Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) - Stewart, M W; Rosenfeld, P J; Penha, F M (Retina, 2012)